Trinity Biotech to Announce Third Quarter 2009 Financial Results on October 21, 2009

DUBLIN, IRELAND--(Marketwire - October 14, 2009) - Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter of 2009 on Wednesday October 21, 2009. The Company has scheduled a conference call for that same day, Wednesday, October 21, 2009, at 11:00am EDT (4:00pm BST) to discuss the results of the quarter.

Interested parties can access the call by dialing:

 USA: 1-800-860-2442 International: 1-412-858-4600 Conference ID #: 434757 

A simultaneous webcast of the call can be accessed at: http://www.videonewswire.com/event.asp?id=62977

A replay of the call can be accessed until October 23, 2009 by dialing:

 USA: 1-877-344-7529 International: 1-412-317-0088 Conference ID #: 434757 

The webcast of the call will be available for 30 days at: http://www.videonewswire.com/event.asp?id=62977

About Trinity Biotech plc

Headquartered in Wicklow, Ireland, Trinity Biotech develops, acquires manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own sales force and a network of international distributors and strategic partners.

For further information please see the company’s website: http://www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company’s periodic reports filed with the Securities and Exchange Commission.